Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CTSC | P53634 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 6/20 | 0.38 |
| ▸ | HTR7 | P34969 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8063332 | 0.90 | CTSL (0.44) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL13662065 | 0.89 | CTSL (0.48) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL4298223 | 0.86 | CTSL (0.48) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL4291992 | 0.85 | CTSL (0.48) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL4297011 | 0.85 | CTSL (0.46) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL4298177 | 0.85 | CTSL (0.46) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL3943998 | 0.83 | CTSL (0.51) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL4290400 | 0.82 | CTSL (0.44) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL4290297 | 0.82 | CTSL (0.44) | CTSLCTSSCTSKCTSCCTSB | |
| SCHEMBL3950947 | 0.82 | CTSL (0.54) | CTSLCTSSCTSKCTSCCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | CTSL 7/4885CTSS 2/4885CTSK 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.